Dalton Announces Sterile Filling Expansion Plan

Share Article

Dalton announces strategic aseptic filling expansion plan. The plan adds capabilities and upgrades to support the growing needs of its customers for sterile filling.

These upgraded capabilities not only increase our overall capacity but allow us to offer more complete and efficient sterile manufacturing services.

Past News Releases


Dalton Pharma Services, a leading provider of drug discovery, development and manufacturing services to pharmaceutical and biotechnology companies, today announced that the company has begun the first stage of its strategic aseptic filling expansion plan. The initial stage, which commenced in January 2013, will add high speed sterile vial processing and washing, an upgraded high purity water system, expanded vial depyrogenation capability, additional lyophilisation capacity and automated vial inspection capability. This phase will also upgrade our personnel access with expanded and improved gowning areas.

The upgraded GMP sterile manufacturing capabilities provide Dalton with an ability to handle larger volume commercial aseptic filling of sterile liquids and sterile powders as well as improve project timelines by eliminating bottlenecks. The new space is being constructed within the existing building footprint.

Later stages of the sterile processing expansion plan will add additional GMP manufacturing facilities, equipment and automation that align with Dalton’s goal of providing fully integrated sterile manufacturing services from preclinical to commercial production, for both sterile API and finished doses.

”The expansion of our sterile liquid and sterile powder filling capabilities is in response to the requirements of our customers," said Peter Pekos, CEO of Dalton. “These upgraded capabilities not only increase our overall capacity but allow us to offer more complete and efficient sterile manufacturing services. This will allow Dalton to provide more cost effective and flexible support for our client’s aseptic drug development and manufacturing requirements. Future stages of this expansion will add high-value capabilities supporting large and small molecule development, in line with the evolving needs of the sterile manufacturing marketplace.”

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and aseptic filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its modern cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts aseptic fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients. Further information can be found at http://www.dalton.com.

For further information, contact:
Peter Pekos
President & CEO
Dalton Pharma Services Inc.
349 Wildcat Road
Toronto, Ontario
Tel: 416-661-2102

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Peter Pekos
Visit website